News
NAUT
2.440
-2.01%
-0.050
Weekly Report: what happened at NAUT last week (0415-0419)?
Weekly Report · 2d ago
Weekly Report: what happened at NAUT last week (0408-0412)?
Weekly Report · 04/15 09:01
Insiders of Nautilus Biotechnology, Inc. (NASDAQ:NAUT) must be frustrated after market cap dropped US$38m since recent purchases
Top 4 shareholders of Nautilus Biotechnology, Inc. (NASDAQ:NAUT) own 54% of the company. The company is owned by institutional investors, with a 33% ownership of the stock. The top 4 shareholders own more than half of the shares in the company . It's interesting to see that insiders have been buying shares recently in Nautilus Biotechnology. The share price fell 10.0% from its previous high of US$120m to US$100m. We look at the company's insider ownership of shares to see what insiders are buying.
Simply Wall St · 04/09 10:07
Weekly Report: what happened at NAUT last week (0401-0405)?
Weekly Report · 04/08 09:02
Weekly Report: what happened at NAUT last week (0325-0329)?
Weekly Report · 04/01 09:02
12 Health Care Stocks Moving In Friday's Pre-Market Session
Avalo Therapeutics stock rose 289.1% to $18.48 during Friday's pre-market session. Xilio Therapeutic (XLO) shares moved upwards by 205.16% during the session. Biodexa Pharmaceuticals (BDRX) shares also moved upwards. Losers NuCana (NCNA) and Yield10 Bioscience (YTEN) fell in the pre- market session.
Benzinga · 03/29 12:06
Weekly Report: what happened at NAUT last week (0318-0322)?
Weekly Report · 03/25 09:02
Weekly Report: what happened at NAUT last week (0311-0315)?
Weekly Report · 03/18 09:02
Weekly Report: what happened at NAUT last week (0304-0308)?
Weekly Report · 03/11 09:02
Weekly Report: what happened at NAUT last week (0226-0301)?
Weekly Report · 03/04 09:02
Analysts Offer Insights on Healthcare Companies: Argenx Se (ARGX), Tenet Healthcare (THC) and Nautilus Biotechnolgy (NAUT)
TipRanks · 03/01 10:10
Nautilus Biotechnology files $300M mixed securities shelf
Seeking Alpha · 02/28 20:51
Nautilus Biotechnology Inc reports results for the quarter ended in December - Earnings Summary
Nautilus Biotechnology Inc reported quarterly adjusted earnings of 14 cents per share for the quarter ended in December. The company reported a quarterly loss of $17.02 million. Wall Street expected the company to report a loss of -19 cents. The average analyst rating on the company's shares is "buy"
Reuters · 02/28 17:19
Nautilus Biotechnology Inc: Current report
Press release · 02/28 16:02
Nautilus Biotechnology GAAP EPS of -$0.14 beats by $0.01
Nautilus Biotechnology's Q4 GAAP EPS of -$0.14 beats by $0.01. Shares +1.02% PM. Cash, cash equivalents, and investments were $264.1 million as of December 31, 2023. 2024 Outlook: We expect to launch our platform, instruments, and software in 2025.
Seeking Alpha · 02/28 13:04
BRIEF-Nautilus Biotechnology Q4 EPS USD -0.14
Reuters · 02/28 13:00
*Nautilus Biotechnology 4Q Loss/Shr 14c >NAUT
Dow Jones · 02/28 13:00
*Nautilus Biotechnology 4Q Loss $17M >NAUT
Dow Jones · 02/28 13:00
Press Release: Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2023 Financial Results
Nautilus Biotechnology reports fourth quarter and fiscal year 2023 financial results. The company is pioneering a single molecule proteome analysis platform. Operating expenses were $76.2 million for the year ended December 31, 2023. Nautilus expects to launch its platform, instruments, and software in 2025.
Dow Jones · 02/28 13:00
Press Release: Nautilus Biotechnology Reports -2-
Three months ended December 31, 2018, Biotechnology, Inc. Reported a net loss of $16.7 million. The company expects to make a profit in the second quarter of this year. The company's net loss per share for the quarter was $0.08. The Company expects to report a profit for the third quarter of 2018.
Dow Jones · 02/28 13:00
More
Webull provides a variety of real-time NAUT stock news. You can receive the latest news about Nautilus Biotechnology Inc through multiple platforms. This information may help you make smarter investment decisions.
About NAUT
Nautilus Biotechnology, Inc. is a development stage life sciences company. The Company is engaged in creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company is focused on transforming the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. The Company's platform end-to-end solution comprised of the proteome analysis system, consumables, and software. The Company’s products include Proteome Analysis System, and Reagent Kits. Its proteome analysis system is a high-resolution optical imaging system coupled with integrated fluidics and liquid handling sub-systems. The Company’s Reagent Kits are comprised of four main components: sample preparation, flow cell(s), multi-affinity probe reagents, and instrument buffers used to perform multi-cycle analysis runs.